Objective: To assess the sensitivity, the number needed to screen (NNS) and the positive predictive value (PPV) of cervical cytology for the diagnosis of cancer by age in a screening population. Methods: A retrospective cohort of women with invasive cervical cancer nested within a census of cervical cytology. All (c. 8 million) women aged 20-64 years with cervical cytology (excluding tests after an earlier abnormality). From April 2007 to March 2010, 3372 women had cervical cancer diagnosed within 12 months of such cytology in England. The sensitivity of cervical cytology to cancer, NNS to detect one cancer and predictive values of cytology were calculated for various 'referral' thresholds. These were calculated for ages 20-24, 25-34, 35-49 and 50-64 years. Results: The sensitivity of at least moderate dyskaryosis [equivalent to a high-grade squamous intraepithelial lesion (HSIL) or worse] for cancer of 89.4% [95% confidence interval (CI) 88.3-90.4%] in women offered screening was independent of age. At all ages, women with borderline-early recall or mild dyskaryosis on cytology (equivalent to ASC-US and LSIL, respectively, in the Bethesda system) had a similar risk of cervical cancer to the risk in all women tested. The PPV of severe dyskaryosis/?invasive and ?glandular neoplasia cytology (equivalent to squamous cell carcinoma and adenocarcinoma/adenocarcinoma in situ, respectively, in the Bethesda System) were 34% and 12%, respectively; the PPV of severe dyskaryosis (HSIL: severe dysplasia) was 4%. The NNS was lowest when the incidence of cervical cancer was highest, at ages 25-39 years, but the proportion of those with abnormal cytology who have cancer was also lowest in younger women. Conclusions: The PPV of at least severe dyskaryosis (HSIL: severe dysplasia) for cancer was 4-10% of women aged 25-64 years, justifying a 2-week referral to colposcopy and demonstrating the importance of failsafe monitoring for such patients. The sensitivity of cytology for cervical cancer was excellent across all age groups.
Introduction
Cervical screening aims to prevent cervical cancer through the diagnosis and treatment of premalignant cervical lesions. Although screening can lead to the early diagnosis of invasive cervical cancer, which is not its primary goal, and the value of cytology to detect cancer (rather than pre-cancerous lesions) has not been studied. This paper considers the results of a census of cervical cytology; we show the distribution of cytology results, by age, in the general (screening) population and women with cervical cancer. We explore the sensitivity and positive predictive value (PPV) of cer-vical cytology at different thresholds for the detection of invasive cervical cancer in the general screening population, as well as the number of women needed to be screened (NNS) to detect one case of invasive cervical cancer.
During the study period (2006-2010) the technology used for screening in England changed. Liquid-based cytology (LBC) was introduced between 2003 and 2008 and will have resulted in cytology slides taken during the study period reported in a combination of conventional cytology and one of the two systems of LBC. In addition, six large cytology laboratories in England were using HPV testing to triage borderline and mild dyskaryosis(equivalent to ASC-US and LSIL, respectively, in the Bethesda system) during most of this period.
Materials and methods
For the results of cytology in women with cervical cancer, we used data from the National Audit of Invasive Cervical Cancers in England. [1] [2] [3] We studied a retrospective cohort of women who had had cervical cytology taken in the 12 months prior to diagnosis, between April 2007 and March 2010. All cervical cytology was read using the British Society for Clinical Cytology (BSCC) terminology in laboratories subject to accreditation and quality assurance. Data on their screening histories were abstracted from cervical cytology records held on the Exeter Call/Recall System. For results in the general population we used an extract from the Exeter database (taken in October/November 2010) including annual attendances to the screening programme from April 2007 to March 2010. 4 This resulted in a census of cytology results. The information in this extract included the women's age, test result and category of screening invitation (for example routine recall, early recall after an abnormality or surveillance after treatment). In both women with cancer and the general population, we excluded cytology that was taken because of an earlier abnormal result. Note that by considering cytology in a 3-year window and excluding repeat tests, few women will have more than one test in this study. 
Results

Cytology results
There were 3372 women diagnosed with cervical cancer, who had a routine (i. Figure 2a . The NNS is lowest when the incidence of cervical cancer is highest, at ages 25-39 years.
In 78% of women aged 20-64 years with cervical cancer with at least one test within 12 months of diagnosis, the first such test was Level 1 and 89% were Level 2. The sensitivity of cytology to cervical cancer was largely independent of age ( Figure 2b) .
Overall, the PPV for cervical cancer of a severe dyskaryosis/?invasive report was 33.5% (95% CI: 31.3-35.8%), the PPV of a report of ?glandular neoplasia was 12.4% (95% CI: 11.4-13.5%) and 3.6% (95% CI: 3.4-3.8%) for a report of severe dyskaryosis ( Table 1 ). The PPV of moderate dyskaryosis was much less: 0.66% (95% CI: 0.57-0.75%) (i.e. 1 in 153 women with moderate dyskaryosis had cervical cancer), which was similar to the PPV of a borderline-high risk (0.61%, 95% CI: 0.52-0.71%). The overall PPV of all Level 2 cytology was 2.77% (95% CI: 2.67-2.87%), whereas the PPV of Level 1 cytology was 5.34% (95% CI: 5.14-5.54%) ( Table 1) . The PPV of Levels 1 and 2 cytology increased with age ( Table 2 ). The PPV of inadequate tests remained below the overall PPV for all women having a cytology test across all ages (0.03% for women aged 25-34 years, 35-49 years and 50-64 years). Trends in PPV of cytology to cancer by age are shown in Figure 2c . The PPVs of mild dyskaryosis (0.07%, 95% CI: 0.05-0.09%) and of borderline-low risk (0.06%, 95% CI: 0.05-0.07%) were similar to the prevalence of cancer in all screened women (0.041%, 95% CI: 0.040-0.042%). In other words, the chance of the cancer being diagnosed in the next year in a woman with mild dyskaryosis is only slightly higher than in a randomly selected woman attending screening (1 in 2436).
Women's first screen
When data for young women were split according to whether it was the woman's first screen or subsequent screen, the proportion of Level 2 results was slightly higher for first screens (age 20-24 years: first screen 4.0%, subsequent screens 3.6%; age 25-29: first screen 3.2%, subsequent screens 2.7%). However, the PPV of a Level 1 cytology result was substantially higher for first screens than subsequent screens, particularly at age (Table 4) . The results were very similar when cytology within 9 or 18 months of diagnosis was considered in place of 12 months (Supplementary Table S2 ).
Discussion
We have shown that in a screening population, regardless of age, the predictive value of cytology for cervical cancer is extremely high for reports of severe dyskaryosis/?invasive carcinoma (34%) and ? glandular neoplasia (12%), and high for reports of severe dyskaryosis (3.6%). Collectively these three groups account for a high proportion (78%) of invasive cervical cancers, and thereby confirm that the current guidelines for a 2-week referral to colposcopy for severe dyskaryosis or worse cytology results are appropriate. Additionally, our results demonstrate the need for failsafe monitoring for women with severe dyskaryosis or worse cytology.
The PPV of severe dyskaryosis or worse (Level 1) cytology was substantially higher on the first cervical screening test in young women than among those who had been screened previously, reflecting the large number of prevalent cancers diagnosed at first screen, although it is important to note that in England 72% of women aged 20-29 years diagnosed with cervical cancer on their first cytology test had stage 1A cancer. 8 These results explain why the number needed to screen is lower and the PPV of cytology to cancer is higher among women under the age of 35 years than among older women. The sensitivity of cytology for cervical cancer is excellent; in fact it is much better than the reported sensitivity for CIN3 or worse. 9 The sensitivity of cytology to cancer was similar across all age groups. Our results show that the risk of cancer in women aged 20-64 years with borderline low-risk or mild dyskaryosis (ASCUS/LSIL) was similar (PPV of borderline-low risk changes or mild dyskaryosis 0.06% and 0.07%, respectively) to that in all women tested (regardless of the result, 0.04%). In contrast, the PPVs of borderline-high risk (0.61%) and moderate dyskaryosis (0.66%) were 15 times higher than the overall risk among screened women.
When interpreting these findings it is important to bear in mind that results refer to the use of cervical cytology for the early diagnosis of cancer, and not the standard use of cytology (i.e. screening for the detection of precursor disease). As such, the NNS will be much higher and predictive values in this paper much lower than those obtained in a screening context.
The main strength of this study is in the use of cytology results for the entire population of England together with the linked screening histories for There has been concern that cytology in the presence of invasive cancer is unreliable because the cytology may be inadequate (or even negative). In this study, we found no evidence (in any age group) to suggest this, and additionally show that the proportion of cytology tests that are inadequate in the presence of cancer remains low across all age groups. As some false-negative cytology does occur, it remains important that GPs follow-up women with gynaecological symptoms of possible cervical cancer, and that they make a specialist referral if symptoms persist or worsen.
A substantial benefit of cervical screening comes from early diagnosis of occult cancers. The NNS to detect one cancer using cervical cytology (2700 per cancer) is considerably higher than the NNS to diagnose one colorectal cancer using faecal occult blood tests (516 per cancer 12 ). However, the incidence of cervical cancer has been reduced by 46% since the introduction of the national screening programme in England in 1988, and it is difficult to estimate what the incidence would be in the absence of screening. This study reports cytology read using BSCC terminology in laboratories subject to accreditation and quality assurance, and the conclusions may not generalize to other systems for reporting cytology or to countries with less quality assurance.
Conclusion
The PPV of severe dyskaryosis or worse cytology for cervical cancer is 4-10% in women aged 25-64 years, clearly justifying a 2-week referral to colposcopy and emphasizing the importance of failsafe monitoring for such patients. The sensitivity of cytology for cervical cancer is excellent across all age groups.
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